The significant upregulation of MX2 in high-risk patients, along with the reduced expression of FAM50B, FUCA1, AKAP6, and FCER1A in this group, further supports their potential roles in tumour progression and immune regulation. This evidence concerns the gene MX2 and neoplasm.